Institutional Review Boards

Our site has experience working with different central IRBs and does not require approval from any organization other than an IRB in order to participate in your clinical trial. Our regulatory specialist guarantees that regulatory documents will be submitted to the IRB within 7 days of receipt at our Site. In many cases this is actually accomplished much faster. The average turnaround time from submission to approval is 3 weeks.

We have experience with the following IRBs:

Chesapeake
Coast
Copernicus
WIRB
Quorum
Schulman
Sterling

New data from the Centers for Disease Control and Prevention (CDC) and from Harvard University, fails to find a link between Menactra, the vaccine currently licensed to protect against meningococcal meningitis in adolescents and adults, and Guillain Barre disease, a neurologic condition. In a study of over 4.5 million 11-18 year olds, there were no cases of Guillain Barre disease in the 45 days after getting Menactra. According to Dr. Carol Baker, the chair of the Meningitis Task Force for the CDC, this study should put to rest any lingering concerns about a relationship between Menactra and Guillain Barre disease.

My irritation "button" is most easily pushed when my child:

A. ignores me when I’m telling him/her what to do.
B. whines and complains.
C. fights with a sibling.
D. talks back or acts rude.
E. some other behavior not listed.